Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Depreciation & Amortization (CF): 2016-2025

Historic Depreciation & Amortization (CF) for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $8.6 million.

  • Ultragenyx Pharmaceutical's Depreciation & Amortization (CF) fell 1.72% to $8.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.3 million, marking a year-over-year increase of 1.76%. This contributed to the annual value of $35.5 million for FY2024, which is 36.67% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Depreciation & Amortization (CF) of $8.6 million as of Q3 2025, which was down 0.15% from $8.6 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Depreciation & Amortization (CF) ranged from a high of $9.1 million in Q4 2024 and a low of $3.1 million during Q2 2021.
  • For the 3-year period, Ultragenyx Pharmaceutical's Depreciation & Amortization (CF) averaged around $8.0 million, with its median value being $8.6 million (2025).
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Depreciation & Amortization (CF) surged by 68.93% in 2024 and then declined by 2.74% in 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Depreciation & Amortization (CF) (Quarterly) stood at $3.5 million in 2021, then spiked by 40.27% to $5.0 million in 2022, then soared by 65.79% to $8.2 million in 2023, then grew by 10.48% to $9.1 million in 2024, then dropped by 1.72% to $8.6 million in 2025.
  • Its Depreciation & Amortization (CF) was $8.6 million in Q3 2025, compared to $8.6 million in Q2 2025 and $9.0 million in Q1 2025.